Adverse drug reaction profile of anticancer agents in a tertiary care centre of rural Maharashtra: a cross-sectional study

Palak Agrawal; Sandeep Narwane; Priyanka Gulve; Prajakta Kolhe; Shreya Singhal; Sonakshi Goyal; Amitesh Shukla

doi:10.18203/2320-6012.ijrms20232782

Authors

Palak Agrawal Department of Pharmacology, Dr. Balasaheb Patil Rural Medical College, Pravara Institute of Medical Sciences Loni, Ahmedagar, Maharashtra, India
Sandeep Narwane Department of Pharmacology, Smt. B. K. Shah Medical Institute & Research Centre, Sumandeep Vidyapeeth, Piparia, Waghodia, Vadodara, Gujarat, India
Priyanka Gulve Department of Pharmacology, Dr. Balasaheb Patil Rural Medical College, Pravara Institute of Medical Sciences Loni, Ahmedagar, Maharashtra, India
Prajakta Kolhe Department of Pharmacology, Dr. Balasaheb Patil Rural Medical College, Pravara Institute of Medical Sciences Loni, Ahmedagar, Maharashtra, India
Shreya Singhal Department of Pharmacology, Dr. Balasaheb Patil Rural Medical College, Pravara Institute of Medical Sciences Loni, Ahmedagar, Maharashtra, India
Sonakshi Goyal Department of Pharmacology, Dr. Balasaheb Patil Rural Medical College, Pravara Institute of Medical Sciences Loni, Ahmedagar, Maharashtra, India
Amitesh Shukla Department of Pharmacology, Dr. Balasaheb Patil Rural Medical College, Pravara Institute of Medical Sciences Loni, Ahmedagar, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20232782

Keywords:

Adverse drug reactions, Pattern, Oncology, Causality assessment

Abstract

Background: The present study was undertaken to analyse the clinical spectrum, pattern of ADR reported, most common suspected drugs, timing of reporting of suspected ADR, outcome, severity and causality assessment of adverse drug reactions among oncology patients reported at our ADR monitoring Centre.

Methods: The descriptive cross-sectional study was carried out for two months in the oncology department of a tertiary care rural hospital. ADR reporting form Version 2.4 was used for recording information of all patients of any gender and age who were suspected cases of adverse drug reactions receiving chemotherapy.

Results: Total 83 ADRs were reported within the duration of two months. The number of males and females were 21 and 62, respectively with mean age 56.9±11.6 years for males and 59.6±8.8 years for females. The age group most commonly reported with suspected ADR was 61-70 years (28.9%). Of the 83 ADR reported, the most common suspected drug was Paclitaxel (47, 56.6%). The most common indications for the use of these anticancer drugs was reported to be CA breast (43, 51.8%). Most of the ADRs (38, 45.8%) were reported immediately. On applying Naranjo’s Causality Assessment Scale, 61 and 22 ADRs fell in the category of Probable and Possible, respectively.

Conclusions: The occurrence of ADR among patients on chemotherapy is high. The reported ADR were common and predictable. Hence diligent monitoring in ADR may help manage and prevent morbidity associated with anti-cancer drugs.

Metrics

Metrics Loading ...

References

Tripathi KD. Essentials of Medical Pharmacology. 7th ed. New Delhi: JP Brothers; 2013:82-91.

Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in‑patients: A prospective analysis of 3695 patient‑episodes. PLoS One 2009;4:e4439.

Ratan JL, Mangala L, Sukirti D. A study on adverse drug reactions in a tertiary care hospital of northeast India. Alex J Med. 2017;53:151-6.

Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4:73-7.

Three-year report of population-based cancer registries: 2012-2014. Available at: http://ncdirindia. org/NCRP/ALL_NCRP_REPORTS/PBCR_REPORT_2012_2014/index.html. Accessed on 20 November 2022.

Maharashtra Cancer Statistics 2020. Available at: https://health.maharashtra.gov.in/MCRI/pdf.pdf. Accessed on 20 February 2022.

Bhise M. Adverse drug reactions in oncology patients in India: An analysis from multiple centers. Indian J Cancer. 2020;57(4):409-13.

Thippeswamy HN. Prospective analysis of adverse drug reactions in cancer patients undergoing chemotherapy in a tertiary care teaching hospital. Indian J Pharmacol. 2019;51(6):394-400.

Nair R. Adverse drug reactions to targeted cancer therapy: A retrospective study of reports in a pharmacovigilance database of South India. Indian J Pharmacol. 2018;50(5):261-8.

Sivagnanam G. Adverse drug reactions in pediatric oncology patients: A prospective observational study. Indian J Cancer. 2018;54(1):205-8.

Aggarwal R. Adverse drug reactions in elderly oncology patients: A prospective observational study. Indian J Pharmacol. 2016;48(4):423-7.

Johnson A. Effect of adverse drug reaction profile reporting on oncology treatment modification and patient outcomes. J Oncol Pharm Pract. 2017;23(3): 183-9.

Safety of Medicines. Available at: http://www.whqlibdoc.who.int/hq/2002/.WHO_EDM_QSM_2002.2.pdf . Accessed on 20 February 2022.

Chabner BA, Amrein PC, Druker BJ. Bruntan LL, Lazo JS, Parker KL. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. USA: MaGraw-Hill Companies Inc; 2006:1315.

Lavan AH, O'Mahony D, Buckley M, O'Mahony D, Gallagher P. Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability. Oncologist. 2019;24(9):e968-e977.

Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: A prospective observational survey. Indian J Med Paediatr Oncol. 2016;37(1):42-6.

Poddar S, Sultana R. Pattern of adverse drug reactions due to cancer chemotherapy in tertiary care teaching hospital in Bangladesh. Dhaka Univ J Pharm Sci. 2009;8:11-6.

Kirthi C, Afzal A, Reddy M, Ali SA, Yerramilli A, Sharma S. A study on the adverse effects of anticancer drugs in an oncology center of a tertiary care hospital. Int J Pharm Pharm Sci. 2014;6:580-3.

Miller MA. Gender-based differences in the toxicity of pharmaceuticals-The food and drug administration's perspective. Int J Toxicol. 2001;20:149-52.

Mallik S, Palaian S, Ojha P, Mishra P. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Nepal. Pak J Pharm Sci. 2007;20:214-8.

Prasad A, Pratim PD, Bhattacharya J, Pattanayak C, Chauhan AS, Panda P. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Eastern India. J Pharmacovigil. 2013;1:107.

ICH Final Guideline on special populations. Available at: https://www.icmr.in. Accessed on 20 February 2022.

Mudigubba A. Risk factors associated with adverse drug reactons in hospitalized patients IJPSR. 20178(9):3847-54.

De A. Monitoring of suspected adverse drug reactions in oncology unit of an urban multispeciality teaching hospital. Int J Res Pharm Biomed Sci. 2010;1:1-32.

Wahlang JB, Laishram PD, Brahma Dk, Sarkar C, Lahon J, Nongkynrih B, Adverse Drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Therapeutic Adv Drug Safety. 2017;8(2):61-6.

Gunaseelan V, Mandal SK, Prasad VN, Khumukcham R, Devi KKP, Singh TT. Adverse drug reactions to cancer chemotherapy in a regional cancer center in Northeast India. Int J Pharm Sci Res. 2014;5:3358.

Mrugank BP, Hareesha RP. Prospective observational, non-randomized, parallel sequence study for assessment of adverse drug reactions due to chemotherapeutic treatment in different types of cancer patients Int J Pharm Sci Res. 2013;4:386

Willson ML, Burke L, Ferguson T, Ghersi D, Nowak AK, Wilcken N. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2019;9(9):CD004421.

Brown A, Kumar S, Tchounwou PB. Cisplatin-Based Chemotherapy of Human Cancers. J Cancer Sci Ther. 2019;11(4):97.

Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22: 7265-79.

Gottesman MM, Fojo TSE. Multidrug resistance in cancer: Role of ATP dependent transporters. Nat Rev Cancer. 2002;2(1):48-58.

Johnson-Arbor K, Dubey R. Doxorubicin. In: StatPearl. Treasure Island (FL): StatPearls Publishing; 2023.

Dutta A, Banerjee A, Basu S, Chaudhry S, Analysis of under reporting of adverse drug reactions: scenario in India and neighbouring countries. Int J Adv Pharmacol. 2021;3(1):45-9.

Ramasubbu SK, Pasricha RK, Nath UK, Das B. Frequency, nature, severity and preventability of adverse drug reactions arising from cancer chemotherapy in a teaching hospital. J Family Med Prim Care. 2020;9:3349-55.

Goyal YN, Solanki KC, Mistry RA, Joshi ND, Singh AP, Gajera MV. Pattern of adverse drug reactions due to cancer chemotherapy in tertiary care teaching hospital in Gujarat. Med Sci 2014;3:333 5.

Singh S, Dhasmana DC, Bisht M, Singh PK. Pattern of adverse drug reactions to anticancer drugs: A quantitative and qualitative analysis. Indian J Med Paediatr. 2017;38:140 5.

Kishore P, Meghana G, Reddy BP, Raghavaiah KV. Pattern of adverse drug reactions and its management in female cancer patients in a private hospital in Telangana, India. Asian J Pharm Res Dev. 2018;6: 45 5.